# Efficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion.

> **NCT06281964** · PHASE3 · ENROLLING_BY_INVITATION · sponsor: **Avistone Biotechnology Co., Ltd.** · enrollment: 327 (estimated)

## Conditions studied

- Non-Small-Cell Lung Cancer

## Interventions

- **DRUG:** PLB1004
- **DRUG:** Pemetrexed+（carboplatin or Cisplatin）with or without Sintilimab

## Key facts

- **NCT ID:** NCT06281964
- **Lead sponsor:** Avistone Biotechnology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2023-12-01
- **Primary completion:** 2028-06-30
- **Final completion:** 2030-06-30
- **Target enrollment:** 327 (ESTIMATED)
- **Last updated:** 2026-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06281964

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06281964, "Efficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06281964. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*